Life (Basel)
Guideline Recommendations for Optimal Anti-VEGF Therapy in AMD
Moraru AD, Danielescu C, Iorga RE, et al
In this review, the authors discuss functional and morphological treatment criteria based on current recommendations and highlight situations where the benefits of continuing therapy are arguable in terms of improving patient quality of life. Optimizing treatment regimens for patients with age-related macular degeneration is important, as they usually have a long follow-up period
- • Deep Learning-Assisted Analysis of Biomarker Changes in Therapy-Resistant Neovascular Age-Related Macular Degeneration
- • Real-World Safety and Efficacy of 8 mg Aflibercept in nAMD
- • Case Report: Aflibercept for DME in Vitrectomized Eyes
- • Guideline Recommendations for Optimal Anti-VEGF Therapy in AMD
- • AI-Assisted Fluid Volume Analysis of Treatment-Naive nAMD in the Real World
- • Consecutive Monthly Loading Administrations of Aflibercept 8 Mg for Treatment-Naïve Exudative AMD
- • Outcomes of High-Dose Aflibercept in Exudative nAMD
- • PULSAR: Intravitreal Aflibercept 8 mg in nAMD
- • PHOTON: Intravitreal Aflibercept 8 mg in Diabetic Macular Edema
- • CANDELA: Aflibercept 8 mg in Patients With nAMD